Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
Sponsor: Frontera Therapeutics
Summary
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
Official title: An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.
Key Details
Gender
MALE
Age Range
8 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2023-02-01
Completion Date
2027-11-01
Last Updated
2023-05-24
Healthy Volunteers
No
Conditions
Interventions
FT-002
Comparison of different dosages of FT-002
Locations (2)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Eye & ENT hospital of Fudan university
Shanghai, Shanghai Municipality, China